OBJECTIVE: To evaluate the efficacy and safety of three antithrombotic agents on @entity1211 ( @entity1211 ) after unilateral total knee arthroplasty. METHODS: From November 2011 to March 2014, 149 @entity1 undergoing unilateral total knee arthroplasty for @entity626 were reviewed. Among them, there were 66 males and 83 females, ranging in age from 48 to 76 years old. All the cases were randomly divided into three groups including @entity117 group, low-molecular-weight heparin (LMWH) group, and @entity3925 group, according to antithrombotic agents. @entity1150 ( @entity1150 ), @entity1151 ( @entity1151 ) and @entity548 complication (including wound ecchymosis, @entity1410 and other local complications, @entity360 and other major @entity548 events) of antithrombotic agents were observed and analyzed statistically at the 6 week, 8 week, and 12 week after operation. RESULTS: Among @entity1 who received @entity117 (48 cases), 4 @entity1 had @entity1150 , in 1 @entity1 had @entity1151 , and 2 @entity1 had @entity548 complication. Among 54 @entity1 in low-molecular-weight @entity6950 group, 3 @entity1 had @entity1150 , 1 @entity1 had @entity1151 , and 3 @entity1 had @entity548 complication. While among those @entity1 received the @entity3925 (47 cases), 3 @entity1 had @entity1150 , 0 @entity1 had @entity1151 , and 11 @entity1 had @entity548 complication. There were no statistically differences among three groups on @entity1150 , and @entity1151 (P>0.05). The incidence of @entity548 complication in @entity3925 group was higher than the other two antithrombotic agents, and the difference among the three groups was statistically significant (P<0.05). CONCLUSION: @entity117 , low-molecular-weight heparin, and @entity3925 could effectively reduce the incidence of @entity1211 after total knee arthroplasty, and their efficacy was similar. @entity3925 has a higher incidence of @entity548 complication and further clinical trials are required to be conducted to assess the safety of @entity3925 in clinical.

[Case-control study on three antithrombotic agents for the prevention of XXXX after unilateral total knee arthroplasty].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['Deep vein thrombosis', 'DVT'] @entity6950 :: ('MESH:D006493', 'Chemical') :: ['heparin'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['Rivaroxaban', 'rivaroxaban'] @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematoma'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal, cardiovascular, urinary hemorrhage']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
